82 results
8-K
EX-99.1
ARVN
Arvinas Inc
16 May 24
Regulation FD Disclosure
6:05am
%); no grade 5 TRAEs or febrile neutropenia were reported. The majority of Grade 4 neutropenia events occurred in the first cycle of treatment
8-K
ARVN
Arvinas Inc
16 May 24
Regulation FD Disclosure
6:05am
%) and decreased white blood cell count (15%); no grade 5 TRAEs or febrile neutropenia were reported.
The majority of Grade 4 neutropenia events occurred
S-8
EX-99.4
y60twui5d jdws2e4j
16 Jan 24
Registration of securities for employees
4:03pm
S-8
EX-99.3
m3u8qsg0z61kt
16 Jan 24
Registration of securities for employees
4:03pm
S-3ASR
nds 0abbv8oi
8 Dec 23
Automatic shelf registration
9:16am
8-K
xj0jff8wd 2js6
6 Dec 23
Regulation FD Disclosure
7:01am
8-K
EX-99.1
3cx4dpqc8dlba9jfg84y
6 Dec 23
Regulation FD Disclosure
7:01am
8-K
EX-10.2
v87hg3
27 Nov 23
Arvinas Announces Oversubscribed $350 Million Private Placement
7:11am
8-K
EX-4.1
rmd hkdkg4c
27 Nov 23
Arvinas Announces Oversubscribed $350 Million Private Placement
7:11am
8-K
EX-10.1
jpt7ei44rz1
27 Nov 23
Arvinas Announces Oversubscribed $350 Million Private Placement
7:11am
S-3ASR
uxknzs
7 Nov 23
Automatic shelf registration
5:24pm
S-3ASR
EX-4.5
eql4ybm8i3qr
7 Nov 23
Automatic shelf registration
5:24pm
S-3ASR
EX-4.4
bgiyp3y7u or
7 Nov 23
Automatic shelf registration
5:24pm
S-3ASR
EX-4.6
4n1i8x1s54c7a6
7 Nov 23
Automatic shelf registration
5:24pm
S-3ASR
EX-4.7
zf3sn 6uv
7 Nov 23
Automatic shelf registration
5:24pm